Información de la revista
Vol. 57. Núm. 1.
Páginas 45-50 (julio 2002)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 57. Núm. 1.
Páginas 45-50 (julio 2002)
Acceso a texto completo
Enfermedad de Fabry: reconocimiento en la edad pediátrica
Fabry'S Disease: Diagnosis In The Pediatric Age Group
Visitas
17960
G. Pintos Morell
Autor para correspondencia
gpintos@ns.hugtip.scs.es

Correspondencia: Servicio de Pediatría. Hospital Universitario Germans Trías i Pujol. Ctra. de Canyet, s/n. 08916 Barcelona. España.
Unidad de Nefrología y Metabolismo Pediátricos. Servicio de Pediatría. Hospital Universitario Germans Trías i Pujol. Universidad Autónoma de Barcelona. España.
Este artículo ha recibido
Información del artículo
Objetivo

La enfermedad de Fabry es la segunda alteración más frecuente por acumulación lisosómica de glucoesfingolípidos (después de la enfermedad de Gaucher). La sintomatología típica de la enfermedad suele empezar a manifestarse a partir de la primera década de la vida. Los síntomas del proceso, como dolor neuropático, afectación gastrointestinal con dolor abdominal, vómitos y diarreas, y manifestaciones cutáneas (angioqueratoma), son motivo de una importante afectación de la calidad de vida. Sin embargo, el diagnóstico de la enfermedad suele hacerse de manera muy diferida, por lo general en el adulto de 20-30 años. Así pues, la finalidad de esta revisión es llamar la atención a la comunidad pediátrica sobre las manifestaciones de la enfermedad de Fabry en el niño, especialmente en este momento en que un tratamiento de sustitución enzimática ha demostrado su efectividad para conseguir la regresión de la enfermedad.

Método

Revisión de la bibliografía dirigida a ofrecer el máximo de información sobre las manifestaciones pediátricas de la enfermedad de Fabry.

Resultados

La sintomatología más frecuente en menores de 16 años consiste en dolor neuropático, angioqueratoma, dolores abdominales, vómitos y diarreas, hipoacusia, proteinuria, alteraciones oftalmológicas, hipohidrosis, fiebre y fenotipo facial característico. La enfermedad de Fabry de inicio en la infancia suele diagnosticarse, en promedio, unos 10 años después del inicio de la sintomatología.

Conclusiones

Un reconocimiento progresivo de la enfermedad de Fabry en la infancia puede permitir el diagnóstico rápido y la instauración de un tratamiento eficaz, evitando la progresión de ésta.

Palabras clave:
Enfermedad de Fabry
Enfermedad por acumulación lisosómica
Infancia
Tratamiento sustitutivo enzimático
Objective

Fabry's disease is the second most frequent alteration of glycosphingolipid lysosomal storage diseases (after Gaucher's disease). Typical symptomatology starts in the first decade of life. Neuropathic pain, gastrointestinal involvement with abdominal pain, vomiting and diarrhea and cutaneous manifestations (angiokeratoma) significantly impair quality of life. However, diagnosis is usually made late, in adults aged 20-30 years old. Thus, the aim of this review is to draw pediatricians' attention to the manifestations of Fabry's disease in infancy and childhood, especially now that enzymatic replacement therapy with proven efficacy is available.

Method

We performed an extensive literature review to present the maximum available information on the pediatric manifestations of Fabry's disease.

Results

The most frequent symptomatology before the age 16 years includes neuropathic pain, angiokeratoma, abdominal pain, vomiting, diarrhea, hypoacousia, proteinuria, ophthalmologic alterations, hypohidrosis, fever, and characteristic facial phenotype. The onset of Fabry's disease may occur in infancy but the mean delay in diagnosis is 10 years after the first symptoms.

Conclusions

Increased awareness of Fabry's disease in infancy and childhood could lead to early diagnosis and treatment thus avoiding disease progression.

Key words:
Fabry disease
Lysosomal storage disease
Infancy
Enzymatic replacement therapy
El Texto completo está disponible en PDF
BibliografÍa
[1.]
P.J. Meikle, J.J. Hopwood, A.E. Clague, W.F. Carey.
Prevalence of lysosomal storage disorders.
Jama, 281 (1999), pp. 249-254
[2.]
B.J. Poorthuis, R.A. Webers, W.J. Kleijer, J.E. Groener, J.G. Jong, S. van Weeley, et al.
The frequency of lysosomal storage diseases in The Netherlands.
Hum Genet, 105 (1999), pp. 151-156
[3.]
J.J. Hopwood, D.A. Brooks.
An introduction to the basic science and biology of the lysosome and storage diseases.
Organelle diseases, pp. 7-35
[4.]
G. Pintos Morell.
Errores congénitos del metabolismo de las organelas celulares.
Medicine, 7 (1999), pp. 6184-6190
[5.]
P.M. Hoogerbrugge, D. Valerio.
Bone marrow transplantation and gen therapy for lysosomal storage diseases.
Bone Marrow Transplant, 21 (1998), pp. S34-S36
[6.]
W.A. Anderson.
A case of angiokeratoma.
Br J Dermatol, 10 (1898), pp. 113-117
[7.]
J. Fabry.
Ein Beitrag Zur Kenntnis der Purpura haemorrhagica nodularis (Purpura papulosa haemorrhagica Hebrae).
Arch Derm Syph, 43 (1898), pp. 187-200
[8.]
R.O. Brady, A.E. Gal, R.M. Bradley, E. Martensson, A.L. Warshaw, L. Laster.
Enzymatic defect in Fabry's disease: Ceramidetrihexosidase deficiency.
N Engl J Med, 276 (1967), pp. 1163-1167
[9.]
R.J. Desnick, Y.A. Ioannou.
Eng CM. α-galactosidasa A deficiency: Fabry disease.
The Metabolic and Molecular Bases of Inherited Disease, 8th, pp. 3733-3774
[10.]
K.D. MacDermot, A. Holmes, A.H. Miners.
Anderson-Fabry disease Clinical manifestations and impact of disease in a cohort of 98 hemizygous males.
J Med Genet, 38 (2001), pp. 750-760
[11.]
M.J. Hilz, B. Stemper, E.H. Kolodny.
Lower limb cold exposure induces pain and prolonged small fiber dysfunction in Fabry patients.
Pain, 84 (2000), pp. 361-365
[12.]
A.N. Rahman, F.A. Simcone, D.B. Hackel, P.W. Hall III, E.Z. Hirsch, J.W. Harris.
Angiokeratoma corporis diffusum universale (hereditary dystopic lipidosis).
Trans Assoc Am Physicians, (1961), pp. 74-366
[13.]
K.J. Sheth, G.C. Bernhard.
The arthropathy of Fabry disease.
Arthritis Rheum, 22 (1979), pp. 781-783
[14.]
E.D. Shelley, W.B. Shelley, T.W. Kurczynski.
Painful fingers, heat intolerance, and telangiectases of the ear: Easily ignored childhood signs of Fabry disease.
Pediatr Dermatol, 12 (1995), pp. 215-219
[15.]
R.O. Brady.
Ophtalmologic aspects of lipid storage diseases.
Ophtalmology, 85 (1978), pp. 1007-1013
[16.]
S.H. Morgan, P. Rudge, S.J. Smith, A.M. Bronstein, B.E. Kendall, E. Holly.
The neurological complications of Anderson Fabry disease (a-galactosidase A deficiency): Investigation of symptomatic and presymptomatic patients.
Q J Med, 75 (1990), pp. 491-507
[17.]
P.A. Schachern, D.A. Shea, M.M. Paparella, T.H. Yoon.
Otologic hystopathology of Fabry's disease.
Ann Otol Rhinol Laryngol, 98 (1989), pp. 359-363
[18.]
M.C. Gubler, G. Lenoir, J.P. Grünfeld, A. Ulmann, D. Droz, R. Habib.
Early renal changes in hemizygous and heterozygous patients with Fabry's disease.
Kidney Int, 13 (1978), pp. 223-235
[19.]
K.J. Sheth, D.A. Roth, A.B. Adams.
Early renal failure in Fabry's disease.
Am J Kidney Dis, 2 (1983), pp. 651-654
[20.]
V.J. Ferrans, R.G. Hibbs, C.D. Burda.
The heart in Fabry's disease A histochemical and electron microscopic study.
Am J Cardiol, 24 (1969), pp. 95-110
[21.]
Y. Ikari, K. Kuwako, T. Yamaguchi.
Fabry's disease with completeatrioventricular block: Histological evidence of involvementof the conduction system.
Br Heart J, 68 (1992), pp. 323-325
[22.]
A. Linhart, T. Palecek, J. Bultas, J.J. Ferguson, J. Hrudova, D. Karetova, et al.
New insights in cardiac structural changes in patientswith Fabry's disease.
Am Heart J, 139 (2000), pp. 1101-1108
[23.]
W. Von Scheidt, C.M. Eng, T.F. Fitzmaurice, E. Erdmann, G. Hubner, E.G. Olsen, et al.
An atypical variant of Fabry's disease withmanifestations confined to the myocardium.
N Engl J Med, 324 (1991), pp. 395-399
[24.]
S. Nakao, T. Takenaka, M. Maeda, C. Kodama, A. Tanaka, M. Tahara, et al.
An atypical variant of Fabry's disease in men with leftventricular hypertrophy.
N Engl J Med, 333 (1995), pp. 288-293
[25.]
P. Mitsias, S.R. Levine.
Cerebrovascular complications of Fabry'sdisease.
Ann Neurol, 40 (1996), pp. 8-17
[26.]
R.P. Grewal, N.W. Barton.
Fabry's disease presenting with stroke.
Clin Neurol Neurosurg, 94 (1992), pp. 177-179
[27.]
G. Tedeschi, S. Bonavita, T.K. Banerjee, A. Virta, R. Sciffmann.
Diffusecentral neuronal involvement in Fabry disease: A protonMRS imaging study.
Neurology, 52 (1999), pp. 1663-1667
[28.]
L.K. Brown, A. Miller, A. Bhuptani, M.F. Sloane, M.I. Zimmerman, G. Schilero, et al.
Pulmonary involvement in Fabry disease.
AmJ Respir Cri Care Med, 155 (1997), pp. 1004-1010
[29.]
M.C. Marguery, F. Giordano, M. Parant, G. Samalens, T. Levade, R. Salvayre, et al.
Fabry's disease: Heterozygous form of differentexpression in two monozygous twin sisters.
Dermatology, 187 (1993), pp. 9-15
[30.]
R.J. Desnick, Y.A. Ioannou, C.M. Eng.
α-galactosidase A deficiency:Fabry disease.
The metabolic and molecular bases of inherited disease. 7th ed.Vol II, pp. 2741-2784
[31.]
C.D. Burda, P.R. Winder.
Angikeratoma corporis diffusum universale(Fabry's disease) in female subjects.
Am J Med, 42 (1967), pp. 293-301
[32.]
K.D. Mac Dermot, A. Holmes, A.H. Miners.
Anderson-Fabry disease:Clinical manifestations and impact of disease in a cohort of60 obligate carrier females.
J Med Genet, 38 (2001), pp. 769-807
[33.]
R.J. Desnick, K.Y. Allen, S.J. Desnick, M.K. Raman, R.W. Bernlohr, W. Krivit.
Fabry's disease: Enzymatic diagnosis of hemizygotesand heterozygotes. Alpha-galactosidase activities in plasma,serum, urine, and leukocytes.
J Lab Clin Med, 81 (1973), pp. 157-171
[34.]
M. Caggana, G.A. Ashley, R.J. Desnick, C.M. Eng.
Fabry disease:Molecular carrier detection and prenatal diagnosis by analysisof closely linked polymorphisms at Xq22.1.
Am J Med Genet, 71 (1997), pp. 329-335
[35.]
R. Kornreich, R.J. Desnick.
Fabry disease: Detection of gene rearrangementsin the human alpha-galactosidase A gene by multiplexPCR amplification.
Hum Mutat, 2 (1993), pp. 108-111
[36.]
W.J. Kleijer, L.M. Hussaarts-Odijk, E.S. Sachs, M.G. Jahoda, M.F. Niermeijer.
Prenatal diagnosis of Fabry's disease by direct analysisof chorionic villi.
Prenat Diagn, 7 (1987), pp. 283-287
[37.]
R.J. Desnick, G. Dawson, S.J. Desnick, C.C. Sweeley, W. Krivit.
Diagnosis of glycosphingolipidoses by urinary-sediment analysis.
N Engl J Med, 284 (1971), pp. 739-744
[38.]
S. Chatterjee, P. Gupta, R.E. Pyeritz, P.O.J. Kwiterovitch.
Immunohistochemical localization of glycosphingolipid in urinary renal tubular cells in Fabry's disease.
Am J Clin Pathol, 82 (1984), pp. 24-28
[39.]
R.C. Pabico, B.C. Atancio, B.A. McKenna, T. Pamukcoglu, R. Yodaiken.
Renal pathologic lesions and functional alterations in a man with Fabry's disease.
Am J Med, 55 (1973), pp. 415-425
[40.]
G. Lenoir, M. Rivron, M.C. Gubler, J.L. Dufier, F.S. Tome, M. Guivarch.
La maladie de Fabry. Traitement du syndrome acrodyniforme par la carbamazepine.
Arch Fr Pediatr, 34 (1977), pp. 704-716
[41.]
L.A. Lockman, D.B. Hunninghake, W. Krivit, R.J. Desnick.
Relief of pain of Fabry's disease by diphenylhydantoin.
Neurology, 23 (1973), pp. 871-875
[42.]
K.E. Gordon, M.D. Ludman, G.A. Finley.
Successful treatment of painful crises of Fabry disease with low-dose morphine.
Pediatr Neurol, 12 (1995), pp. 250-251
[43.]
A. Ojo, H.U. Meier-Kriesche, G. Friedman, J. Hanson, D. Cibrik, A. Leichtman.
Excellent outcome of renal transplantation in patients with Fabry's disease.
Transplantation, 69 (2000), pp. 2337-2339
[44.]
E.J. Schweitzer, C.B. Drachenberg, S.T. Bartlett.
Living kidney donor and recipient evaluation in Fabry's disease.
Transplantation, 54 (1992), pp. 924-927
[45.]
W.J. Cantor, P. Daly, M. Iwanochko, J.T. Clarke, R.J. Cusimano, J. Butani.
Cardiac transplantation for Fabry's disease.
Can J Cardiol, 14 (1998), pp. 81-84
[46.]
R.O. Brady, J.F. Tallman, W.G. Johnson, A.E. Gal, W.R. Leahy, J.M. Quirk, et al.
Replacement therapy for inherited enzyme deficiency.Use of purified ceramidetrihexosidase in Fabry's disease.
N Engl J Med, 289 (1973), pp. 9-14
[47.]
R. Schiffmann, G.J. Murray, D. Treco, P. Daniel, M. Sellos-Moura, M. Myers, et al.
Infusion of a-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease.
Proc Natl Acad Sci (USA), 97 (2000), pp. 365-370
[48.]
R. Schiffmann, J.B. Kopp, H.A. Austin III, S. Sabnis, D.F. Moore, T. Weibel, et al.
Enzyme replacement therapy in Fabry disease.A randomized controlled trial.
Jama, 285 (2001), pp. 2743-2749
[49.]
C.M. Eng, N. Guffon, W.R. Wilcox, D.P. Germain, P. Lee, S. Waldek, et al.
Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease.
N Engl J Med, 345 (2001), pp. 9-16
[50.]
A. Abe, S. Gregory, L. Lee, P.D. Killen, R.O. Brady, A. Kulkarni, et al.
Reduction of globotriaosylceramide in Fabry disease mice by substrate deprivation.
J Clin Invest, 105 (2000), pp. 1563-1571
[51.]
S.C. Jung, I.P. Han, A. Limaye, R. Xu, M.P. Gelderman, P. Zerfas, et al.
Adeno-associated viral vector-mediated gene transfer results in long-term enzymatic and functional correction in multiple organs of Fabry mice.
Proc Natl Acad Sci (USA), 98 (2001), pp. 2676-2681
[52.]
T. Takenaka, G.J. Murray, G. Qin, J.M. Quirk, T. Ohshima, P. Qasba, et al.
Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Proc Natl Acad Sci (USA), 97 (2000), pp. 7515-7520
Copyright © 2002. Asociación Española de Pediatría
Descargar PDF
Idiomas
Anales de Pediatría
Opciones de artículo
Herramientas
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?